232 related articles for article (PubMed ID: 26178698)
1. CX3CR1 is a gatekeeper for intestinal barrier integrity in mice: Limiting steatohepatitis by maintaining intestinal homeostasis.
Schneider KM; Bieghs V; Heymann F; Hu W; Dreymueller D; Liao L; Frissen M; Ludwig A; Gassler N; Pabst O; Latz E; Sellge G; Penders J; Tacke F; Trautwein C
Hepatology; 2015 Nov; 62(5):1405-16. PubMed ID: 26178698
[TBL] [Abstract][Full Text] [Related]
2. CX3CR1-expressing inflammatory dendritic cells contribute to the progression of steatohepatitis.
Sutti S; Locatelli I; Bruzzì S; Jindal A; Vacchiano M; Bozzola C; Albano E
Clin Sci (Lond); 2015 Nov; 129(9):797-808. PubMed ID: 26253086
[TBL] [Abstract][Full Text] [Related]
3. Obesity, fatty liver disease and intestinal microbiota.
Arslan N
World J Gastroenterol; 2014 Nov; 20(44):16452-63. PubMed ID: 25469013
[TBL] [Abstract][Full Text] [Related]
4. Intestinal Microbiota Protects against MCD Diet-Induced Steatohepatitis.
Schneider KM; Mohs A; Kilic K; Candels LS; Elfers C; Bennek E; Schneider LB; Heymann F; Gassler N; Penders J; Trautwein C
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646522
[TBL] [Abstract][Full Text] [Related]
5. Altered Gut Microbiota Composition and Immune Response in Experimental Steatohepatitis Mouse Models.
Ishioka M; Miura K; Minami S; Shimura Y; Ohnishi H
Dig Dis Sci; 2017 Feb; 62(2):396-406. PubMed ID: 27913996
[TBL] [Abstract][Full Text] [Related]
6. CX3CL1/CX3CR1 interaction protects against lipotoxicity-induced nonalcoholic steatohepatitis by regulating macrophage migration and M1/M2 status.
Ni Y; Zhuge F; Ni L; Nagata N; Yamashita T; Mukaida N; Kaneko S; Ota T; Nagashimada M
Metabolism; 2022 Nov; 136():155272. PubMed ID: 35914622
[TBL] [Abstract][Full Text] [Related]
7. Fructo-oligosaccharides and intestinal barrier function in a methionine-choline-deficient mouse model of nonalcoholic steatohepatitis.
Matsumoto K; Ichimura M; Tsuneyama K; Moritoki Y; Tsunashima H; Omagari K; Hara M; Yasuda I; Miyakawa H; Kikuchi K
PLoS One; 2017; 12(6):e0175406. PubMed ID: 28632732
[TBL] [Abstract][Full Text] [Related]
8. CXC chemokine receptor 3 promotes steatohepatitis in mice through mediating inflammatory cytokines, macrophages and autophagy.
Zhang X; Han J; Man K; Li X; Du J; Chu ES; Go MY; Sung JJ; Yu J
J Hepatol; 2016 Jan; 64(1):160-70. PubMed ID: 26394162
[TBL] [Abstract][Full Text] [Related]
9. Heme-oxygenase-1 Production by Intestinal CX3CR1
Marelli G; Erreni M; Anselmo A; Taverniti V; Guglielmetti S; Mantovani A; Allavena P
Cancer Res; 2017 Aug; 77(16):4472-4485. PubMed ID: 28619710
[TBL] [Abstract][Full Text] [Related]
10. Non-redundant role of the chemokine receptor CX3CR1 in the anti-inflammatory function of gut macrophages.
Marelli G; Belgiovine C; Mantovani A; Erreni M; Allavena P
Immunobiology; 2017 Feb; 222(2):463-472. PubMed ID: 27707514
[TBL] [Abstract][Full Text] [Related]
11. Diets rich in fructose, fat or fructose and fat alter intestinal barrier function and lead to the development of nonalcoholic fatty liver disease over time.
Sellmann C; Priebs J; Landmann M; Degen C; Engstler AJ; Jin CJ; Gärttner S; Spruss A; Huber O; Bergheim I
J Nutr Biochem; 2015 Nov; 26(11):1183-92. PubMed ID: 26168700
[TBL] [Abstract][Full Text] [Related]
12. Fat-laden macrophages modulate lobular inflammation in nonalcoholic steatohepatitis (NASH).
Jindal A; Bruzzì S; Sutti S; Locatelli I; Bozzola C; Paternostro C; Parola M; Albano E
Exp Mol Pathol; 2015 Aug; 99(1):155-62. PubMed ID: 26112094
[TBL] [Abstract][Full Text] [Related]
13. Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model.
Douhara A; Moriya K; Yoshiji H; Noguchi R; Namisaki T; Kitade M; Kaji K; Aihara Y; Nishimura N; Takeda K; Okura Y; Kawaratani H; Fukui H
Mol Med Rep; 2015 Mar; 11(3):1693-700. PubMed ID: 25421042
[TBL] [Abstract][Full Text] [Related]
14. CX3CR1 regulates intestinal macrophage homeostasis, bacterial translocation, and colitogenic Th17 responses in mice.
Medina-Contreras O; Geem D; Laur O; Williams IR; Lira SA; Nusrat A; Parkos CA; Denning TL
J Clin Invest; 2011 Dec; 121(12):4787-95. PubMed ID: 22045567
[TBL] [Abstract][Full Text] [Related]
15. Depletion of Gut Microbiota Protects against Renal Ischemia-Reperfusion Injury.
Emal D; Rampanelli E; Stroo I; Butter LM; Teske GJ; Claessen N; Stokman G; Florquin S; Leemans JC; Dessing MC
J Am Soc Nephrol; 2017 May; 28(5):1450-1461. PubMed ID: 27927779
[TBL] [Abstract][Full Text] [Related]
16. NASH: CX3CR1-a direct line to gut-liver crosstalk?
Patman G
Nat Rev Gastroenterol Hepatol; 2015 Sep; 12(9):490. PubMed ID: 26239845
[No Abstract] [Full Text] [Related]
17. Antibiotics attenuate diet-induced nonalcoholic fatty liver disease without altering intestinal barrier dysfunction.
Brandt A; Csarmann K; Hernández-Arriaga A; Baumann A; Staltner R; Halilbasic E; Trauner M; Camarinha-Silva A; Bergheim I
J Nutr Biochem; 2024 Jan; 123():109495. PubMed ID: 37871765
[TBL] [Abstract][Full Text] [Related]
18. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
[TBL] [Abstract][Full Text] [Related]
19. Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease.
Utzeri E; Usai P
World J Gastroenterol; 2017 Jun; 23(22):3954-3963. PubMed ID: 28652650
[TBL] [Abstract][Full Text] [Related]
20. Unique microbial-derived volatile organic compounds in portal venous circulation in murine non-alcoholic fatty liver disease.
Reid DT; McDonald B; Khalid T; Vo T; Schenck LP; Surette MG; Beck PL; Reimer RA; Probert CS; Rioux KP; Eksteen B
Biochim Biophys Acta; 2016 Jul; 1862(7):1337-44. PubMed ID: 27085070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
